<DOC>
	<DOCNO>NCT00048217</DOCNO>
	<brief_summary>Patients complete study T1249-102 ( must currently fail T-20 contain regimen participate study ) receive T-1249 dose 200mg daily combination background antiretroviral regimen 96 week . Only patient participate study T1249-102 participate study T1249-105 .</brief_summary>
	<brief_title>A Rollover Study Provide Chronic T-1249 Patients Who Completed Study T1249-102</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Completion T1249102 ; Currently fail T20 contain regimen Noncompletion T1249102 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>